Clinical Trials on Japanese

Total 107 results

Orthomedico Inc.
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED

Completed

The Effect of Oral Hyaluronic Acid (UltraHA®) on the Knee Function

Healthy Japanese Subjects

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants

Healthy Japanese Participants

Japan
Bloomage Biotechnology Corp., Ltd.

Completed

The Effect of Oral Hyaluronic Acid on the Skin

Healthy Japanese Subjects

Japan
AstraZeneca

Completed

A Single and Multiple Dose Study to Assess Blood and Urine Drug Levels of Fostamatinib in Healthy Japanese Subjects

Healthy Japanese Volunteers

United States
Orthomedico Inc.
ECA Healthcare Inc.

Active, not recruiting

Effects of Consumption of Phosphatidylserine on the Cognitive Function

Healthy Japanese Subjects

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects

Healthy Japanese Volunteers

United Kingdom
mAbxience Research S.L.

Completed

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Healthy Volunteers | Male | Japanese

Japan
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

Healthy Japanese Male Adults
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

A Bioequivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Males

Japan
Takeda

Completed

Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

Japanese Healthy Adult Males

Japan
Takeda

Completed

A Food Effect Study of TAK-385 Final Formulation

Japanese Premenopausal Healthy Adult Women

Japan
AstraZeneca

Completed

Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects

Pharmacokinetics | Bioequivalence | Healthy Japanese Subjects

United Kingdom
Eisai Co., Ltd.

Completed

E2022 Patch Formulation Single Dose Phase I Study

Japanese Healthy Male Adult Volunteers

Japan
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects

Healthy Japanese and Caucasian Subjects

United Kingdom
EA Pharma Co., Ltd.

Completed

A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects

Japanese Healthy Adult Male Participants

Japan
Takeda

Withdrawn

Phase 1 Single Subcutaneous Dose Study of MLN1202

Healthy Japanese and Caucasian Male Adults

Japan
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Healthy Subjects | Pharmacokinetics | Pharmacodynamics | Japanese | Caucasian

Germany
Pfizer

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

Healthy Male and Female Japanese Volunteers

United States
AstraZeneca

Completed

A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years

Healthy Japanese Children Age 7 Years Through 18 Years

Japan
AstraZeneca

Completed

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

Healthy Japanese Children Age 2 Years Through 6 Years

Japan
Takeda

Completed

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Japanese Healthy Adult Male Participants

Japan
AstraZeneca

Completed

A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers

Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers

Japan
Medical University of Vienna
Valneva Austria GmbH

Unknown

Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.

Japanese Encephalitis Vaccine

Austria
Indian Institute of Science
Wellcome Trust; PATH; University of Liverpool; National Institute of Mental Health...

Completed

A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2

Japanese Encephalitis | Japanese Encephalitis Vaccine

India
Mahidol University

Completed

Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children (JE0153)

Encephalitis, Japanese B

Thailand
PATH
Quintiles, Inc.; Mahidol University; Research Institute for Tropical Medicine...

Completed

Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Encephalitis, Japanese B

Philippines
Cancer Institute and Hospital, Chinese Academy...

Active, not recruiting

Purified Inactivated Japanese Encephalitis Vaccine

Japanese Encephalitis Virus Disease

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers

Japanese Encephalitis | Japanese Encephalitis Virus Disease

Korea, Republic of
PATH

Completed

Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Encephalitis, Japanese B

Philippines
Astellas Pharma Inc

Completed

A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects

Pharmacokinetics of ASP3325 in Non-elderly, Healthy Adult Japanese Male and Female, and Caucasian Male Subjects

Japan
Siriraj Hospital
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Encephalitis
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam (JECEVAX-3)

Japanese Encephalitis

Vietnam
National Institute of Hygiene and Epidemiology,...
Ministry of Health, Vietnam; Ministry of Science and Technology, Vietnam

Completed

Safety and Immunogenicity of JECEVAX in Young Children

Japanese Encephalitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Post-licensure Safety Study of IMOJEV® in Thailand

Japanese Encephalitis

Thailand
Valneva Austria GmbH

Completed

Safety Surveillance After Immunization With IXIARO

Japanese Encephalitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Japanese Encephalitis | Encephalitis

Thailand
Khon Kaen University

Unknown

Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children

Japanese Encephalitis

Thailand
University of Liverpool
B.P. Koirala Institute of Health Sciences; Kanti Children's Hospital

Completed

Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis

Japanese Encephalitis

Nepal
Valneva Austria GmbH

Withdrawn

Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination

Japanese Encephalitis

United Kingdom
University of Liverpool

Completed

Flavivirus Cross-priming Potential of IMOJEV (FlaviPrime)

Japanese Encephalitis

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

Japanese Encephalitis

Vietnam
PATH
Mahidol University; Ministry of Health of Sri Lanka; Quintiles Singapore

Completed

Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (JEV03)

Japanese Encephalitis

Sri Lanka

3

Subscribe